PARABDRUGS

Parabolic Drugs Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on February 13, 2013, has decided to shift its corporate office from its existing situation at 9 A.B., Taimoor Nagar, New Friends Colony, New Delhi To S.C.O. 99-100, Third Floor, Sector 17 B, Chandigarh.

Parabolic Drugs Limited has informed the Exchange that the Board of Directors of the Company at its Meeting held on February 13, 2013:(1) Approved the resignation of Mr. Gurpeet Singh Sandhu from the Directorship of the Company.

Parabolic Drugs Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2012.

Parabolic Drugs Limited has informed the Exchange that Mr. Inder Bir Singh Passi and Mr. Koppisetty Srinivas has resigned from the Directorship of the Company. Further, Mr. Balwan Bansal has been appointed as an Additional Director on the Board of Directors of the Company.

Parabolic Drugs Limited has informed the Exchange that the Board of Directors in its Meeting held on November 10, 2012: (a) Approved the resignation of Mr. Manmohan Lai Sarin from the Directorship of the Company. (b) Accorded its consent for making reference to the Corporate Debt Restructuring (CDR) Cell for Financial Restructuring of the Debts of the Company under CDR Mechanism formulated by Reserve Bank of India.

Parabolic Drugs Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2012 with Limited Review Report.

Parabolic Drugs Limited has submitted to the Exchange a copy of the Minutes of the Annual General Meeting of the Company held on September 28, 2012.

Parabolic Drugs Limited has informed the Exchange regarding the Outcome of the Annual General Meeting of the Company held on September 28, 2012.

Parabolic Drugs Limited has informed the Exchange that the Register of Members and Share Transfer books of the Company will remain close from September 26, 2012 to September 28, 2012 (both days inclusive) for Annual Book Closure and determine the entitlement of the members for the dividend, if any, declared by the members in the Annual General Meeting.

Parabolic Drugs Limited has informed the Exchange vide letter dated August 16, 2012 regarding a press release dated August 14, 2012, titled "Parabolic Drugs' Q1 FY 13 sales up 64% to Rs 305.20 Crores, Launches new products in the non-antibiotic segment, The Board of Directors recommends a dividend of Rs.0.25 per share".

Parabolic Drugs Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on August 14, 2012, inter alia, has recommend dividend @ Rs. 0.25 per share on fully paid up equity shares of the Company for the year 2011-2012.

Parabolic Drugs Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2012.

Parabolic Drugs Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2012.

Parabolic Drugs Limited has informed the Exchange vide notes to Accounts in the Unaudited Financial Results for the quarter ended March 31, 2012 (taken on record by the Board of Directors of the Company at its meeting held on May 12, 2012) regarding the Utilisation of funds.

Parabolic Drugs Limited has informed the Exchange, vide its letter dated May 12, 2012, regarding a press release, titled "Parabolic Drugs' FY12 Sales up 50.3% to Rs 1014.9 crore Net Profit at 51.4 Cr".

Parabolic Drugs Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended March 31,2012.

Parabolic Drugs Limited has informed the Exchange vide its letter dated March 29, 2012 regarding "Commissioning of Sterile Cephalosporin Plant at Derabassi".

Parabolic Drugs Limited has informed the Exchange vide notes to Accounts in the Unaudited Financial Results for the quarter ended December 31, 2011 (taken on record by the Board of Directors of the Company at its meeting held on February 11, 2012) regarding the Utilisation of funds.

Parabolic Drugs Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2011.

Parabolic Drugs Limited has informed the Exchange, vide its letter dated February 11, 2012, regarding a press release dated February 11, 2012, titled "Parabolic Drugs' 9M FY12 sales up 54.39% to Rs 719.51 crore; Net profit up 13.66% to Rs.42.39 Crore".

Parabolic Drugs Limited has informed the Exchange, vide its letter dated November 12, 2011, regarding a press release, titled "Parabolic Drugs' H1FY12 sales up 39.49% to Rs 420.66 crore; Net Profit up 19.12% to Rs.29.57 Crore".

Parabolic Drugs Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2011.

Parabolic Drugs Limited has informed the Exchange vide its letter dated October 31, 2011 regarding a press release, titled "Parabolic Drugs gets Japanese nod for Cephalosporin Drugs".

Parabolic Drugs Limited has submitted to the Exchange a copy of the minutes of the Annual General Meeting of the Company held on September 29, 2011.

Parabolic Drugs Limited has informed the Exchange that the members of the Company at its Annual General Meeting held on September 29, 2011: (1) Appointed Mr. Manmohan Lal Sarin as a Director in place of Mr. Pardeep Diwan, who retired by rotation in accordance with the provisions of Articles of Association of the Company; (2) Approved the appointments of Mr. Gurpreet Singh Sandhu and Mr. Nikhil Goel as the Directors of the Company w.e.f September 29, 2011. (3) Approved the appointment of Mr. Gurpreet Singh Sandhu as the Executive Director of the Company w.e.f November 01, 2010 to October 31, 20

PNG Trading Private Limited has submitted to the Exchange a copy of Disclosure under Regulation 13 of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

PNG Trading Private Limited has submitted to the Exchange a copy of Disclosure under Regulation 13 (2), 13(2A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Parabolic Drugs Limited has informed the Exchange that the Annual General Meeting of the Company will be held on September 29, 2011. The Register of Members and the Share Transfer Books of the Company will remain closed from September 21, 2011 to September 29, 2011 (both days inclusive) for the purpose of Dividend.

Parabolic Drugs Limited has informed the Exchange vide its letter dated September 02, 2011 regarding a press release, titled "Parabolic Drugs adds 15% capacity to its Cephalosporin facility commissions its 8th Multi-purpose plant at Derabassi facility".

Parabolic Drugs Limited has informed the Exchange vide its letter dated August 13, 2011 regarding a press release with respect to performance of the Company for the quarter ended June 30, 2011.

Parabolic Drugs Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on August 13, 2011: (1) Approved the resignation of Mr. Anil Kumar from the post of Company Secretary w.e.f.May 23, 2011. (2) Approved the appointment of Mr. Vipin Gupta as Vice President & Company Secretary w.e.f August 05, 2011. (3) Appointed Mr. Vipin Gupta as the Compliance Officer in place of Mr. Anil Kumar. The Board, however, deferred the item on Agenda regarding issuance of Convertible Warrants on preferential basis.

Parabolic Drugs Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on August 13, 2011 has recommended dividend @ Rs.0.50 per share, for the financial year 2010-2011, on fully paid up equity shares of the Company.

Parabolic Drugs Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2011.

Parabolic Drugs Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2011.

Parabolic Drugs Limited has informed the Exchange that the Board of Directors in its meeting held on May 13, 2011: (1) Approved the reconstitution of Remuneration Committee and Investor Grievance Committee of the Company. (2) Recommended the amendment in the terms and conditions of the Prospectus dated June 24, 2010 of the Company.

Parabolic Drugs Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2011.

Parabolic Drugs Limited has submitted to the Exchange the details of Annual statement of Holdings of Shares of the Company, Pursuant to provisions of SEBI (Insider Trading) Regulation, 2002.

Parabolic Drugs Limited has informed the Exchange vide its letter dated April 18, 2011 regarding a press release with respect to Certificate of Suitability (COS) granted to the Company in respect of its one of key molecule namely "Cefixime".

Parabolic Drugs Limited has informed the Exchange that w.e.f. December 2009, the Company got the Credit Ratings for its bank facilities from Credit Analysis and Research Limited (CARE). CARE had given a rating of CARE BB (Double B) and PR4 to the company in December 2009 and has recently upgraded the Credit Ratings of the Company to CARE BBB- (Triple B minus) and PR3 in December 2010.

Parabolic Drugs Limited has informed the Exchange that the Board of Director in its meeting held on February 01, 2011: (1) In accordance with the order of the Ministry of Corporate Affairs, the Company has appointed M/s Anil Sharma & Co., Cost Accountants as the Cost Auditor of the Company. (2) Approved the reconstitution of Share Transfer Committee of the Board. (3) Approved the appointment of Dr. Deepali Gupta, relative of the Directors as an employee of the Company.

Parabolic Drugs Limited has informed the Exchange, vide its letter dated February 02, 2011, regarding a press release, titled "Parabolic Drugs' 9MFY11 net profit up 65.6% to Rs.37.30 crore; Sales up 24.4% to Rs.466.04 crore".

Parabolic Drugs Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2010.

Parabolic Drugs Limited has informed the Exchange that the Company has successfully completed the first phase of its expansion programme initiated in 2008 with the commissioning of Multi-Purpose Plant II comprising of 5 manufacturing blocks for parallel production in Derabassi, Punjab. With the commissioning of MP II, the company has added 325 TPA capacities at its Cephalosporin campus at Derabassi, resulting in a total production capacity of 773 TPA.

Parabolic Drugs Limited has submitted to the Exchange a copy of abstract and memorandum of interest u/s 302 of the Companies Act, 1956.

Parabolic Drugs Limited has informed the Exchange that the Board of Directors in its meeting held on November 08, 2010: (1) Approved the Resignation of Dr. Deepali Gupta from the directorship of the Company w.e.f. November 08, 2010. (2) Approved the Appointments of Mr. Gurpeet Singh Sandhu and Mr. Nikhil Goel as the Additional Directors of the Company w.e.f. November 08, 2010.(3) Recommended the Appointment of Mr. Gurpreet Singh Sandhu as the Whole Time Director of the Company w.e.f. November 08, 2010.

Parabolic Drugs Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2010.

Parabolic Drugs Limited has informed the Exchange regarding the Outcome of the Annual General Meeting of the Company held on September 28, 2010.

Parabolic Drugs Limited has informed the Exchange that the Board of Directors of the Company have decided to hold Annual General Meeting of its members on September 28, 2010 and have further decided to close Register of Members and Share Transfer Books of the Company as Annual Book Closure from September 21, 2010 to September 28, 2010 (both days inclusive) for the purpose of Annual General Meeting.

Parabolic Drugs Limited has submitted to the Exchange a copy of Disclosure under Section 13(1) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992.

Parabolic Drugs Limited has informed the Exchange regarding a press release dated July 12, 2010, titled "Parabolic Drugs Gets EU GMP Approval for its facility".